Sangamo Therapeutics Raises $25M Through New Stock Offering
Sangamo Therapeutics announces a $25 million stock and warrant offering to strengthen its finances and support general business needs.
/ 904 items
#Healthcare↓
Guggenheim Starts Coverage on Sagimet Biosciences with Buy Rating
Guggenheim analyst gives Sagimet Biosciences a Buy rating with $27 target, citing promising results for its FASN inhibitor in MASH and acne.
FDA Grants Breakthrough Status to Zovegalisib for Advanced Breast Cancer
Relay Therapeutics' (RLAY) zovegalisib receives FDA Breakthrough Therapy designation for treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor treatment.
Pfizer Q4 2025: Strong Performance Despite COVID Decline
Pfizer beats Q4 estimates with $17.6B revenue as legacy drugs offset COVID sales drop. Obesity drug shows 12.3% weight loss. 2026 guidance reaffirmed.
Clear Street Starts Coverage on Caribou Biosciences with Buy Rating
Clear Street initiates coverage of Caribou Biosciences with a Buy rating and a $13 price target, highlighting strong CAR-T pipeline potential.
Acadia Pharmaceuticals Faces EU Setback for Rett Syndrome Drug Trofinetide
Acadia Pharmaceuticals (ACAD) receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request.